Innate immune stimulation by monophosphoryl lipid A prevents chronic social defeat stress-induced anxiety-like behaviors in mice

Li, Fu; Xiang, Haitao; Gu, Yue; Ye, Ting; Lu, Xu; Huang, Chao

doi:10.1186/s12974-021-02377-8

Journal of Neuroinflammation

Table 1 Statistical data for the results in each figure

From: Innate immune stimulation by monophosphoryl lipid A prevents chronic social defeat stress-induced anxiety-like behaviors in mice

Figure 1
Figure 1B	EPM test: time spent in open arms	Significant effects: CSDS: F_1,72 = 14.19, p < 0.001 vehicle/MPL: F_3,72 = 3.10, p < 0.05 CSDS × vehicle/MPL interaction: F_3,72 = 3.29, p < 0.05
Figure 1C	EPM test: number of entries into open arms	Significant effects: CSDS: F_1,72 = 11.05, p < 0.01 vehicle/MPL: F_3,72 = 3.85, p < 0.05 CSDS × vehicle/MPL interaction: F_3,72 = 6.38, p < 0.001
Figure 1D	EPM test: number of entries into total arms	No significant effects: CSDS: F_1,72 = 0.05, p = 0.82 vehicle/MPL: F_3,72 = 0.09, p = 0.96 CSDS × vehicle/MPL interaction: F_3,72 = 0.002, p = 0.10
Figure 1E	LDT: time spent in lit side	Significant effects: CSDS: F_1,72 = 12.21, p < 0.001 vehicle/MPL: F_3,72 = 4.30, p < 0.01 CSDS × vehicle/MPL interaction: F_3,72 = 3.02, p < 0.05
Figure 1F	LDT: number of total transitions in both lit and dark side	No significant effects: CSDS: F_1,72 = 0.46, p = 0.50 vehicle/MPL: F_3,72 = 0.70, p = 0.56 CSDS × vehicle/MPL interaction: F_3,72 = 0.17, p = 0.91
Figure 1G	OFT: time spent in the center region of the open field	Significant effects: CSDS: F_1,72 = 11.09, p < 0.01 vehicle/MPL: F_3,72 = 3.51, p < 0.05 CSDS × vehicle/MPL interaction: F_3,72 = 4.13, p < 0.01
Figure 1H	OFT: total distance	No significant effects: CSDS: F_1,72 = 0.008, p = 0.93, vehicle/MPL: F_3,72 = 0.25, p = 0.86 CSDS × vehicle/MPL interaction: F_3,72 = 0.03, p = 0.99
Figure 2
Figure 2B: model 1	EPM test: time spent in open arms	Significant effects: CSDS: F_1,36 = 16.54, p < 0.001 vehicle/MPL: F_1,36 = 7.64, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 4.48, p < 0.05
Figure 2C: model 1	EPM test: number of entries into open arms	Significant effects: CSDS: F_1,36 = 5.06, p < 0.05 vehicle/MPL: F_1,36 = 7.79, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 8.82, p < 0.01
Figure 2D: model 1	EPM test: number of entries into total arms	No significant effects: CSDS: F_1,36 = 0.51, p = 0.48 vehicle/MPL: F_1,36 = 0.08, p = 0.78 CSDS × vehicle/MPL interaction: F_1,36 = 1.42, p = 0.24
Figure 2E: model 1	LDT: time spent in lit side	Significant effects: CSDS: F_1,36 = 15.08, p < 0.001 vehicle/MPL: F_1,36 = 6.53, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 12.13, p < 0.01
Figure 2F: model 1	LDT: number of total transitions in both lit and dark side	No significant effects: CSDS: F_1,36 = 0.02, p = 0.89 vehicle/MPL: F_1,36 = 0.27, p = 0.60 CSDS × vehicle/MPL interaction: F_1,36 = 0.05, p = 0.83
Figure 2G: model 1	OFT: time spent in the center region of the open field	Significant effects: CSDS: F_1,36 = 12.06, p < 0.01 vehicle/MPL: F_1,36 = 8.33, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 4.98, p < 0.05
Figure 2H: model 1	OFT: total distance	No significant effects: CSDS: F_1,36 = 0.02, p = 0.88 vehicle/MPL: F_1,36 = 0.37, p = 0.55 CSDS × vehicle/MPL interaction: F_1,36 = 0.07, p = 0.79
Figure 2B: model 2	EPM test: time spent in open arms	Significant effects: CSDS: F_1,36 = 13.59, p < 0.001 vehicle/MPL: F_1,36 = 5.41, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 11.92, p < 0.01
Figure 2C: model 2	EPM test: number of entries into open arms	Significant effects: CSDS: F_1,36 = 5.41, p < 0.05 vehicle/MPL: F_1,36 = 4.58, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 9.43, p < 0.01
Figure 2D: model 2	EPM test: number of entries into total arms	No significant effects: CSDS: F_1,36 = 0.27, p = 0.61 vehicle/MPL: F_1,36 = 0.16, p = 0.69 CSDS × vehicle/MPL interaction: F_1,36 = 1.54, p = 0.22
Figure 2E: model 2	LDT: time spent in lit side	Significant effects: CSDS: F_1,36 = 8.97, p < 0.01 vehicle/MPL: F_1,36 = 5.93, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 10.22, p < 0.01
Figure 2F: model 2	LDT: number of total transitions in both lit and dark side	No significant effects: CSDS: F_1,36 = 0.19, p = 0.67 vehicle/MPL: F_1,36 = 0.36, p = 0.55 CSDS × vehicle/MPL interaction: F_1,36 = 0.75, p = 0.39
Figure 2G: model 2	OFT: time spent in the center region of the open field	Significant effects: CSDS: F_1,36 = 15.85, p < 0.001 vehicle/MPL: F_1,36 = 6.06, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 11.74, p < 0.01
Figure 2H: model 2	OFT: total distance	No significant effects: CSDS: F_1,36 = 0.07, p = 0.79 vehicle/MPL: F_1,36 = 0.03, p = 0.87 CSDS × vehicle/MPL interaction: F_1,36 = 0.0001, p = 0.10
Figure 2B: model 3	EPM test: time spent in open arms	significant effect: CSDS: F_1,36 = 34.20, p < 0.001 No significant effects: vehicle/MPL: F_1,36 = 0.03, p = 0.85 CSDS × vehicle/MPL interaction: F_1,36 = 0.93, p = 0.34
Figure 2C: model 3	EPM test: number of entries into open arms	significant effect: CSDS: F_1,36 = 13.77, p < 0.001 No significant effects: vehicle/MPL: F_1,36 = 0.14, p = 0.71 CSDS × vehicle/MPL interaction: F_1,36 = 0.28, p = 0.60
Figure 2D: model 3	EPM test: number of entries into total arms	No significant effects: CSDS: F_1,36 = 1.18, p = 0.28 vehicle/MPL: F_1,36 = 0.002, p = 0.97 CSDS × vehicle/MPL interaction: F_1,36 = 0.30, p = 0.59
Figure 2E: model 3	LDT: time spent in lit side	significant effect: CSDS: F_1,36 = 19.96, p < 0.001 No significant effects: vehicle/MPL: F_1,36 = 0.99, p = 0.33 CSDS × vehicle/MPL interaction: F_1,36 = 0.23, p = 0.64
Figure 2F: model 3	LDT: number of total transitions in both lit and dark side	No significant effects: CSDS: F_1,36 = 0.69, p = 0.41 vehicle/MPL: F_1,36 = 0.58, p = 0.45 CSDS × vehicle/MPL interaction: F_1,36 = 0.19, p = 0.67
Figure 2G: model 3	OFT: time spent in the center region of the open field	significant effect: CSDS: F_1,36 = 29.00, p < 0.001 No significant effects: vehicle/MPL: F_1,36 = 0.37, p = 0.55 CSDS × vehicle/MPL interaction: F_1,36 = 0.13, p = 0.73
Figure 2H: model 3	OFT: total distance	No significant effects: CSDS: F_1,36 = 0.24, p = 0.63 vehicle/MPL: F_1,36 = 0.27, p = 0.60 CSDS × vehicle/MPL interaction: F_1,36 = 0.16, p = 0.69
Figure 3
Figure 3B	EPM test: time spent in open arms	Significant effects: CSDS: F_1,36 = 21.85, p < 0.001 vehicle/MPL: F_1,36 = 4.42, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 10.07, p < 0.01
Figure 3C	EPM test: number of entries into open arms	Significant effects: CSDS: F_1,36 = 9.79, p < 0.01 vehicle/MPL: F_1,36 = 4.91, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 6.14, p < 0.05
Figure 3D	EPM test: number of entries into total arms	No significant effects: CSDS: F_1,36 = 0.10, p = 0.79 vehicle/MPL: F_1,36 = 0.38, p = 0.54 CSDS × vehicle/MPL interaction: F_1,36 = 0.86, p = 0.36
Figure 3E	LDT: time spent in lit side	Significant effects: CSDS: F_1,36 = 8.73, p < 0.01 vehicle/MPL: F_1,36 = 7.37, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 15.48, p < 0.001
Figure 3F	LDT: number of total transitions in both lit and dark side	No significant effects: CSDS: F_1,36 = 0.57, p = 0.46 vehicle/MPL: F_1,36 = 0.16, p = 0.69 CSDS × vehicle/MPL interaction: F_1,36 = 0.57, p = 0.46
Figure 3G	OFT: time spent in the center region of the open field	Significant effects: CSDS: F_1,36 = 16.43, p < 0.001 vehicle/MPL: F_1,36 = 8.48, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 14.81, p < 0.001
Figure 3H	OFT: total distance	No significant effects: CSDS: F_1,36 = 0.0009, p = 0.98 vehicle/MPL: F_1,36 = 0.30, p = 0.59 CSDS × vehicle/MPL interaction: F_1,36 = 0.03, p = 0.86
Figure 4
Figure 4B	EPM test: time spent in open arms	Significant effects: CSDS: F_1,54 = 11.65, p < 0.01 vehicle/MPL: F_2,54 = 3.18, p < 0.05 CSDS × vehicle/MPL interaction: F_2,54 = 3.57, p < 0.05
Figure 4C	EPM test: number of entries into open arms	Significant effects: CSDS: F_1,54 = 18.51, p < 0.001 vehicle/MPL: F_2,54 = 4.09, p < 0.05 CSDS × vehicle/MPL interaction: F_2,54 = 6.87, p < 0.01
Figure 4D	EPM test: number of entries into total arms	No significant effects: CSDS: F_1,54 = 0.12, p = 0.73 vehicle/MPL: F_2,54 = 0.49, p = 0.61 CSDS × vehicle/MPL interaction: F_2,54 = 0.11, p = 0.89
Figure 4E	LDT: time spent in lit side	Significant effects: CSDS: F_1,54 = 19.37, p < 0.001 vehicle/MPL: F_2,54 = 3.54, p < 0.05 CSDS × vehicle/MPL interaction: F_2,54 = 6.07, p < 0.01
Figure 4F	LDT: number of total transitions in both lit and dark side	No significant effects: CSDS: F_1,54 = 0.02, p = 0.90 vehicle/MPL: F_2,54 = 0.26, p = 0.77 CSDS × vehicle/MPL interaction: F_2,54 = 0.56, p = 0.58
Figure 4G	OFT: time spent in the center region of the open field	Significant effects: CSDS: F_1,54 = 19.80, p < 0.001 vehicle/MPL: F_2,54 = 6.21, p < 0.01 CSDS × vehicle/MPL interaction: F_2,54 = 3.55, p < 0.05
Figure 4H	OFT: total distance	No significant effects: CSDS: F_1,54 = 0.02, p = 0.89 vehicle/MPL: F_2,54 = 0.49, p = 0.61 CSDS × vehicle/MPL interaction: F_2,54 = 0.07, p = 0.94
Figure 5
Figure 5A	Hippocampal IL-1β	Significant effects: CSDS: F_1,36 = 27.89, p < 0.001 vehicle/MPL: F_1,36 = 9.79, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 11.58, p < 0.01
Figure 5B	Hippocampal IL-6	Significant effects: CSDS: F_1,36 = 28.76, p < 0.001 vehicle/MPL: F_1,36 = 8.14, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 9.54, p < 0.01
Figure 5C	Hippocampal TNF-α	Significant effects: CSDS: F_1,36 = 10.38, p < 0.01 vehicle/MPL: F_1,36 = 4.48, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 4.96, p < 0.05
Figure 5D	Cortical IL-1β	Significant effects: CSDS: F_1,36 = 25.63, p < 0.001 vehicle/MPL: F_1,36 = 9.55, p < 0.01 CSDS × vehicle/MPL interaction: F_1,36 = 6.74, p < 0.05
Figure 5E	Cortical IL-6	Significant effects: CSDS: F_1,36 = 12.93, p < 0.001 vehicle/MPL: F_1,36 = 5.85, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 7.08, p < 0.05
Figure 5F	Cortical TNF-α	Significant effects: CSDS: F_1,36 = 14.57, p < 0.001 vehicle/MPL: F_1,36 = 4.16, p < 0.05 CSDS × vehicle/MPL interaction: F_1,36 = 6.93, p < 0.05
Figure 6
Figure 6A	Hippocampal IL-6	Significant effects: vehicle/MPL: F_1,28 = 50.33, p < 0.001 minocycline: F_1,28 = 26.69, p < 0.001 vehicle/MPL × minocycline interaction: F_1,28 = 21.18, p < 0.001
Figure 6A	Hippocampal IL-1β	Significant effects: vehicle/MPL: F_1,28 = 39.74, p < 0.001 minocycline: F_1,28 = 21.01, p < 0.001 vehicle/MPL × minocycline interaction: F_1,28 = 18.68, p < 0.001
Figure 6B	Cortical IL-6	Significant effects: vehicle/MPL: F_1,28 = 35.22, p < 0.001 minocycline: F_1,28 = 18.53, p < 0.001 vehicle/MPL × minocycline interaction: F_1,28 = 16.03, p < 0.001
Figure 6B	Cortical IL-1β	Significant effects: vehicle/MPL: F_1,28 = 32.60, p < 0.001 minocycline: F_1,28 = 21.23, p < 0.001 vehicle/MPL × minocycline interaction: F_1,28 = 16.66, p < 0.001
Figure 6D	EPM test: time spent in open arms	Significant effects: vehicle/MPL: F_1,36 = 11.15, p < 0.01 minocycline: F_1,36 = 7.66, p < 0.01 vehicle/MPL × minocycline interaction: F_1,36 = 5.20, p < 0.05
Figure 6E	EPM test: number of entries into open arms	Significant effects: vehicle/MPL: F_1,36 = 15.24, p < 0.001 minocycline: F_1,36 = 6.48, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 5.65, p < 0.01
Figure 6F	EPM test: number of entries into total arms	No significant effects: vehicle/MPL: F_1,36 = 1.35, p = 0.25 minocycline: F_1,36 = 0.13, p = 0.72 vehicle/MPL × minocycline interaction: F_1,36 = 0.39, p = 0.54
Figure 6G	LDT: time spent in lit side	Significant effects: vehicle/MPL: F_1,36 = 7.55, p < 0.01 minocycline: F_1,36 = 10.60, p < 0.01 vehicle/MPL × minocycline interaction: F_1,36 = 5.74, p < 0.05
Figure 6H	LDT: number of total transitions in both lit and dark side	No significant effects: vehicle/MPL: F_1,36 = 0.008, p = 0.93 minocycline: F_1,36 = 0.60, p = 0.38 vehicle/MPL × minocycline interaction: F_1,36 = 0.10, p = 0.76
Figure 6I	OFT: time spent in the center region of the open field	Significant effects: vehicle/MPL: F_1,36 = 9.39, p < 0.01 minocycline: F_1,36 = 6.78, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 4.59, p < 0.05
Figure 6J	OFT: total distance	No significant effects: vehicle/MPL: F_1,36 = 0.78, p = 0.38 minocycline: F_1,36 = 0.42, p = 0.52 vehicle/MPL × minocycline interaction: F_1,36 = 0.44, p = 0.51
Figure 7
Figure 7A	Hippocampal IL-1β	Significant effects: vehicle/MPL: F_1,36 = 10.07, p < 0.01 minocycline: F_1,36 = 6.25, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 10.65, p < 0.01
Figure 7B	Hippocampal IL-6	Significant effects: vehicle/MPL: F_1,36 = 4.68, p < 0.05 minocycline: F_1,36 = 5.64, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 10.12, p < 0.01
Figure 7C	Hippocampal TNF-α	Significant effects: vehicle/MPL: F_1,36 = 7.96, p < 0.01 minocycline: F_1,36 = 6.07, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 11.44, p < 0.01
Figure 7D	Cortical IL-1β	Significant effects: vehicle/MPL: F_1,36 = 12.13, p < 0.01 minocycline: F_1,36 = 5.70, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 15.00, p < 0.001
Figure 7E	Cortical IL-6	Significant effects: vehicle/MPL: F_1,36 = 13.01, p < 0.001 minocycline: F_1,36 = 4.76, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 7.06, p < 0.05
Figure 7F	Cortical TNF-α	Significant effects: vehicle/MPL: F_1,36 = 11.16, p < 0.01 minocycline: F_1,36 = 4.29, p < 0.05 vehicle/MPL × minocycline interaction: F_1,36 = 9.41, p < 0.01

Back to article page

ISSN: 1742-2094

Contact us

Submission enquiries: journalsubmissions@springernature.com